四環醫藥(00460.HK):重組III型膠原蛋白凝膠敷料等三項產品獲醫療器械註冊證
格隆匯3月1日丨四環醫藥(00460.HK)發佈公吿,集團旗下渼顏空間生物科技(吉林)有限公司自主研發的重組III型膠原蛋白凝膠敷料、皮膚修復敷料及醫用皮膚修復敷貼三款產品獲得中國國家藥品監督管理局頒發的醫療器械註冊證。
本次獲批的三款皮膚修復類產品均為含III型膠原蛋白成分的II類醫療器械,主要聚焦於解決醫美術後的傷口癒合及疤痕修復這兩大痛點。產品中的主要成分膠原不僅能保護皮膚,促進皮膚組織合成代謝和細胞再生,保持角質層水分以及纖維結構的完整性,改善皮膚細胞生存環境,加速局部皮膚組織的血液循環和新陳代謝,加速組織再生與修復的作用,直接改善皮膚的屏障功能。除了在皮膚表面形成保濕及修復皮膚屏障,該三類產品還有助於改善皮炎、濕疹、敏感性皮膚引起的乾燥脱屑、紅斑等症狀。另外,重組III型膠原蛋白凝膠敷料還可用於激光術後修復、外科術後傷口修復等,不僅能加快受損組織的修復和再生,有效預防瘢痕的形成,也可修復和淡化新生皮膚疤痕,讓術後效果更理想。此三款皮膚修復產品與集團的多款醫美產品具備良好的協同效用,在年內上市後能夠形成有效且互補的產品組合。
此次重組III型膠原蛋白凝膠敷料、皮膚修復敷料及醫用皮膚修復敷貼三款產品獲批,是渼顏空間繼童顏水凝嘉樂妍®、醫用皮膚護理╱修復凝膠及醫用疤痕修復類產品獲批後又新增的三款自研產品,不僅證明了渼顏空間強大的研發實力和快速註冊的能力,同時也標誌着集團醫美產品自研管線的進一步落地,而且豐富和擴大了集團醫美平台渼顏空間的產品組合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.